Clinical Trial Update: Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

The study evaluated the safety and efficacy of P276-00 in relapsed and/or refractory multiple myeloma across Phase 1 and Phase 2 and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• P276-00 (P276-00)

Snippet

Sponsor: Piramal Enterprises Limited | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED